View in EDS

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.

Saved in:
Bibliographic Details
Title: Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.
Authors: Neves JS; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal., Leite AR; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal., Vasques-Nóvoa F; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal., Pitt B; Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA., Filippatos G; Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Ruilope LM; Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain.; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.; Faculty of Sport Sciences, European University of Madrid, Madrid, Spain., Rossing P; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Anker SD; Department of Cardiology (CVK) of German Heart Center Charité, German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany., Savarese G; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden., Scott CAB; Clinical Statistics and Analytics, Bayer Corporation, Whippany, New Jersey, USA., Lage A; Cardiology and Nephrology Clinical Development, Bayer SA, São Paulo, Brazil., Brinker MD; Cardiology and Nephrology Clinical Development, Bayer AG, Leverkusen, Germany., Ferreira JP; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Jul; Vol. 28 (7), pp. 6022-6033. Date of Electronic Publication: 2026 Apr 24.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42027097
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Neves+JS%22">Neves JS</searchLink>; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal.<br /><searchLink fieldCode="AU" term="%22Leite+AR%22">Leite AR</searchLink>; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal.<br /><searchLink fieldCode="AU" term="%22Vasques-Nóvoa+F%22">Vasques-Nóvoa F</searchLink>; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.<br /><searchLink fieldCode="AU" term="%22Pitt+B%22">Pitt B</searchLink>; Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.<br /><searchLink fieldCode="AU" term="%22Filippatos+G%22">Filippatos G</searchLink>; Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Ruilope+LM%22">Ruilope LM</searchLink>; Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain.; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.; Faculty of Sport Sciences, European University of Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Rossing+P%22">Rossing P</searchLink>; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Anker+SD%22">Anker SD</searchLink>; Department of Cardiology (CVK) of German Heart Center Charité, German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Savarese+G%22">Savarese G</searchLink>; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Scott+CAB%22">Scott CAB</searchLink>; Clinical Statistics and Analytics, Bayer Corporation, Whippany, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Lage+A%22">Lage A</searchLink>; Cardiology and Nephrology Clinical Development, Bayer SA, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Brinker+MD%22">Brinker MD</searchLink>; Cardiology and Nephrology Clinical Development, Bayer AG, Leverkusen, Germany.<br /><searchLink fieldCode="AU" term="%22Ferreira+JP%22">Ferreira JP</searchLink>; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100883645%22">Diabetes, obesity & metabolism</searchLink> [Diabetes Obes Metab] 2026 Jul; Vol. 28 (7), pp. 6022-6033. <i>Date of Electronic Publication: </i>2026 Apr 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100883645 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1463-1326 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214628902%22">14628902 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Obes Metab <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42027097
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/dom.70750
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 6022
    Titles:
      – TitleFull: Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Neves JS
      – PersonEntity:
          Name:
            NameFull: Leite AR
      – PersonEntity:
          Name:
            NameFull: Vasques-Nóvoa F
      – PersonEntity:
          Name:
            NameFull: Pitt B
      – PersonEntity:
          Name:
            NameFull: Filippatos G
      – PersonEntity:
          Name:
            NameFull: Ruilope LM
      – PersonEntity:
          Name:
            NameFull: Rossing P
      – PersonEntity:
          Name:
            NameFull: Anker SD
      – PersonEntity:
          Name:
            NameFull: Savarese G
      – PersonEntity:
          Name:
            NameFull: Scott CAB
      – PersonEntity:
          Name:
            NameFull: Lage A
      – PersonEntity:
          Name:
            NameFull: Brinker MD
      – PersonEntity:
          Name:
            NameFull: Ferreira JP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2026 Jul
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1463-1326
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Diabetes, obesity & metabolism
              Type: main
ResultId 1